Corporate Profile

RAPT Therapeutics (formerly FLX Bio) is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.

Utilizing our proprietary discovery and development engine, we develop highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases.
We have discovered and advanced two unique drug candidates each targeting CCR4: our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. We are also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.